Program
dostarlimab
Also written as “Dostarlimab”, “TSR-042” and “Dostarlimab (TSR-042)”.
Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 2 companies.
Drug pageDostarlimab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 2517 open or running | phase 4since Mar 20, 2025 | Mar 9, 2016 | Nov 23, 2026phase 2 · NCT06567782 |
| AGO Research | 10 open or running | phase 2since Oct 18, 2021 | Oct 18, 2021 | none ahead |
Also a collaborator on its studies: iTeos Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Mar 9, 2016 to Oct 18, 2021.
- Jun 9, 2018Named dostarlimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, TSR-042
- Feb 2, 20232 phase 2 studiesGlaxoSmithKline · NCT05723562, NCT05751629
- May 3, 2023Phase 3 study in Colonic NeoplasmsGlaxoSmithKline · NCT05855200 · 892 planned · United States, Argentina, Australia and more
- Feb 5, 2024Phase 3 study in Head and Neck NeoplasmsGlaxoSmithKline · NCT06256588 · 864 planned · United States, Argentina, Australia and more
- Mar 12, 2024Phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311 · 41 enrolled · Japan
- Jun 18, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT06472076 · 88 enrolled · United States, Argentina, Belgium and more
- Aug 20, 2024Phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782 · 120 planned · Belgium, Italy, Japan and more
- Oct 10, 20242 phase 2 studiesGlaxoSmithKline · NCT06640049, NCT06655818
- Mar 20, 2025Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT06897527 · 100 planned
- Aug 5, 2025Phase 2 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07108270 · 30 planned · China
- Jun 11, 2026Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07652515 · 100 planned
- Jul 24, 2026Phase 3 study in Rectal NeoplasmsGlaxoSmithKline · NCT07740720 · 100 planned · Japan
- Sep 30, 2026Phase 3 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07860450 · 378 planned
- Nov 2, 2026Primary completion moved from 2026-07-15 to 2026-12-14Date moved laterphase 2 · +5 months · NCT06317311
- Nov 16, 2026Primary completion moved from 2029-12-12 to 2030-03-13Date moved laterphase 3 · +3 months · NCT07740720
Ahead
- Nov 2, 2026Primary completion: phase 2 study in Rectal NeoplasmsGlaxoSmithKline · NCT05723562
- Nov 23, 2026Primary completion: phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782
- Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
- Dec 14, 2026Primary completion: phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07860450Endometrial Neoplasms | 3 | Not yet recruiting | GlaxoSmithKline | Nov 5, 2030 | 378 |
| NCT07740720Rectal Neoplasms · Japan | 3 | Not yet recruiting | GlaxoSmithKline | Mar 13, 2030 | 100 |
| NCT07652515Endometrial Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Aug 30, 2030 | 100 |
| NCT07108270Endometrial Neoplasms · China | 2 | Recruiting | GlaxoSmithKline | Mar 31, 2030 | 30 |
| NCT06897527Endometrial Neoplasms | 4 | Not yet recruiting | GlaxoSmithKline | Jan 13, 2027 | 100 |
| NCT06655818Multiple Myeloma · France, Korea, Republic of | 2 | Terminated | GlaxoSmithKline | Feb 14, 2024 | 4 |
| NCT06640049Rectal Neoplasms · China | 2 | Active, not recruiting | GlaxoSmithKline | Oct 24, 2027 | 23 |
| NCT06567782Colonic Neoplasms · Belgium, Italy, Japan and more | 2 | Recruiting | GlaxoSmithKline | Nov 23, 2026 | 120 |
| NCT06472076Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 30, 2026 | 88 |
| NCT06317311Carcinoma · Japan | 2 | Active, not recruiting | GlaxoSmithKline | Dec 14, 2026 | 41 |
| NCT06256588Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Jun 30, 2028 | 864 |
| NCT05855200Colonic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | GlaxoSmithKline | Mar 19, 2029 | 892 |
| NCT05751629Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Apr 1, 2022 | 41 |
| NCT05723562Rectal Neoplasms · United States, Canada, France and more | 2 | Active, not recruiting | GlaxoSmithKline | Nov 2, 2026 | 154 |
| NCT05126342Ovarian Neoplasms | 2 | Withdrawn | AGO Research | Nov 1, 2024 | 0 |
| NCT04655976Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 5, 2025 | 758 |
| NCT04544995Neoplasms · United Kingdom | 1 | Terminated | GlaxoSmithKline | Apr 23, 2025 | 47 |
| NCT04581824Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Terminated | GlaxoSmithKline | Aug 4, 2022 | 243 |
| NCT04126200Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 208 |
| NCT03981796Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Nov 26, 2026 | 785 |
| NCT03955471Ovarian Neoplasms · United States | 2 | Terminated | GlaxoSmithKline | Aug 18, 2021 | 41 |
| NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more | 3 | Active, not recruiting | GlaxoSmithKline | Oct 31, 2024 | 1,400 |
| NCT03574779Ovarian Neoplasms · United States, Canada, Spain | 2 | Completed | GlaxoSmithKline | Jun 28, 2024 | 77 |
| NCT03308942Neoplasms · United States | 2 | Completed | GlaxoSmithKline | May 4, 2020 | 53 |
| NCT03307785Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Feb 26, 2020 | 60 |
| NCT02715284Neoplasms · United States, Argentina, Brazil and more | 1 | Active, not recruiting | GlaxoSmithKline | May 18, 2026 | 729 |
How it is read
Names in the registry
- “Dostarlimab”, 22 entries
- “TSR-042”, 2 entries
- “Dostarlimab (TSR-042)”, 1 entry
- “TSR-042 (Dostarlimab)”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 5 studies
- Endometrial Neoplasms, 4 studies
- Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Rectal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.